Hasbro Analyst Starts Coverage Optimistically; Check Out the Top 5 Initiations for Monday
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 10 2025
0mins
Should l Buy LLY?
Source: Benzinga
Analyst Coverage Initiations: Several Wall Street analysts have initiated coverage on various companies, providing ratings and price targets for their stocks.
Solstice Advanced Materials: RBC Capital's Arun Viswanathan rated Solstice Advanced Materials (SOLS) as Sector Perform with a price target of $50, while shares closed at $47.49.
Ascentage Pharma Group: BTIG's Justin Zelin rated Ascentage Pharma (AAPG) as Buy with a price target of $50, with shares closing at $31.73.
Super League Enterprise and Hasbro: Aegis Capital rated Super League Enterprise (SLE) as Buy with a price target of $5, and Seaport Global rated Hasbro (HAS) as Buy with a price target of $100, with respective closing prices of $1.18 and $76.70.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1023.220
Low
950.00
Averages
1192
High
1500
Current: 1023.220
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of Vertex Pharmaceuticals' Future Growth Prospects
- Past Performance: Vertex Pharmaceuticals achieved an 18.2% compound annual growth rate (CAGR) over the past decade, which, while outperforming the market average, is insufficient to turn $100,000 into $1 million, highlighting challenges for future growth.
- Market Potential: Although Vertex's cystic fibrosis (CF) product line will continue to drive growth, the limited patient population suggests that its CF business alone is unlikely to achieve the necessary growth in the next decade, especially with impending patent expirations and competitive pressures.
- Pipeline Prospects: The two candidates in development, inaxaplin and povetacicept, aim to treat diseases with no current medications, and if approved, could provide new growth avenues; however, flawless clinical execution and sustained market leadership will be critical for success.
- Investment Consideration: Even if Vertex may not meet the ambitious goal of turning $100,000 into $1 million, its consistent revenue generation and the introduction of new products like Journavx make its stock worth considering, particularly in light of a more diversified product lineup in the coming decade.
See More
Vertex Pharmaceuticals' Growth Outlook for the Next Decade
- Growth Potential Analysis: To turn $100,000 into $1 million in a decade, Vertex Pharmaceuticals needs to achieve nearly a 26% compound annual growth rate, significantly above the market's long-term average, despite its past decade's CAGR of 18.2%.
- Market Challenges: While Vertex's cystic fibrosis (CF) products will continue to drive growth, the shrinking patient population suggests that its CF business alone may struggle to deliver the necessary growth in the next decade, especially with patent expirations looming.
- Pipeline Candidates: Vertex's pipeline drugs inaxaplin and povetacicept aim to treat currently untreatable diseases, which could provide new growth avenues if approved, but flawless clinical execution will be crucial for success.
- Stock Investment Value: Even if Vertex cannot achieve a 100% success rate, its consistent revenue from CF products and new launches like Journavx make its stock a worthwhile investment, with a more diversified product lineup expected in the next decade.
See More
S&P 500 Bull Market Continues, Investor Confidence High
- Bull Market Performance: The S&P 500 finished 2025 with a remarkable 78% three-year increase, reflecting investor optimism particularly in high-growth sectors like artificial intelligence and weight loss drugs.
- Interest Rate Impact: The Federal Reserve's interest rate cuts have eased consumer financial pressure and facilitated borrowing for companies, which has driven stock prices and valuations higher, with the S&P 500's price-to-earnings ratio reaching historical highs.
- Valuation Fluctuations: Although the S&P 500 has shown little change recently, the Shiller CAPE ratio has declined for the first time, indicating that stock valuations may be coming down, which could signal potential market corrections ahead.
- Long-Term Investment Confidence: Despite potential short-term market fluctuations, historical data shows that the S&P 500 always recovers over the long term, encouraging investors to remain focused on economic reports and Fed signals to seize future investment opportunities.
See More
S&P 500 Index Enters Third Year of Bull Market
- Bull Market Performance: The S&P 500 finished 2023 with a double-digit gain, bringing its three-year increase to 78%, reflecting investor optimism particularly in high-growth sectors like artificial intelligence and weight loss drugs.
- Interest Rate Policy Impact: The Federal Reserve's interest rate cuts have eased consumer financial pressure and made borrowing easier for companies, further fueling stock market gains as investor expectations for economic improvement rise.
- Valuation Changes: The Shiller CAPE ratio for the S&P 500 recently declined for the first time in nearly a year, albeit slightly, marking the first sign of falling valuations; historical patterns suggest that such declines often precede stock market drops, prompting investor caution.
- Long-Term Investment Confidence: Despite potential short-term market fluctuations, the S&P 500 has historically shown resilience over the long term, indicating that investors holding quality stocks may experience limited impact from short-term downturns, with significant returns likely in the future.
See More
S&P 500 Index Surges Nearly 80% Over Three Years
- Bull Market Continuation: The S&P 500 index has entered a bull market since October 2023, achieving a double-digit gain by year-end, resulting in a 78% increase over three years, reflecting strong investor confidence in high-growth sectors, particularly in AI and weight loss drugs.
- Surging Valuations: As the S&P 500 has risen, stock valuations have reached historical highs, with the Shiller CAPE ratio exceeding 40 earlier this year, indicating optimistic expectations for future growth, yet raising concerns about sustainability.
- Interest Rate Policy Impact: The Federal Reserve's interest rate cuts have alleviated consumer burdens and facilitated corporate borrowing, further propelling the stock market; however, investor concerns regarding future rate changes may affect market sentiment, leading to volatility.
- Uncertain Market Outlook: Despite the recent slight decline in the Shiller CAPE ratio, historical data suggests that valuation drops often coincide with stock market declines, prompting investors to monitor economic reports and Fed communications to gauge future market direction.
See More
Novo Nordisk Faces Challenges and Opportunities Amid Setbacks
- Declining Performance: Novo Nordisk's disappointing guidance for fiscal year 2026 has led to a nearly 15% drop in stock price, reflecting pressures from intensified competition and government drug price negotiations that could impact long-term growth potential.
- New Product Launch: The launch of the oral version of Wegovy has seen rapid prescription growth, indicating its potential to generate new revenue streams despite market competition, which could help mitigate some of the company's challenges.
- Market Expansion: Eli Lilly's executive noted that Oral Wegovy is attracting mostly new patients, suggesting that it is not merely cannibalizing existing sales but effectively expanding the market, thereby enhancing Novo Nordisk's competitive position.
- Future Outlook: Despite the short-term sales decline challenges, Novo Nordisk is awaiting approval for new drugs like CagriSema and has several candidates in clinical trials; if progress is made, it could lead to a stock rebound, making it attractive for long-term investors.
See More
Analysis of Vertex Pharmaceuticals' Future Growth Prospects
- Past Performance: Vertex Pharmaceuticals achieved an 18.2% compound annual growth rate (CAGR) over the past decade, which, while outperforming the market average, is insufficient to turn $100,000 into $1 million, highlighting challenges for future growth.
- Market Potential: Although Vertex's cystic fibrosis (CF) product line will continue to drive growth, the limited patient population suggests that its CF business alone is unlikely to achieve the necessary growth in the next decade, especially with impending patent expirations and competitive pressures.
- Pipeline Prospects: The two candidates in development, inaxaplin and povetacicept, aim to treat diseases with no current medications, and if approved, could provide new growth avenues; however, flawless clinical execution and sustained market leadership will be critical for success.
- Investment Consideration: Even if Vertex may not meet the ambitious goal of turning $100,000 into $1 million, its consistent revenue generation and the introduction of new products like Journavx make its stock worth considering, particularly in light of a more diversified product lineup in the coming decade.
See More
Vertex Pharmaceuticals' Growth Outlook for the Next Decade
- Growth Potential Analysis: To turn $100,000 into $1 million in a decade, Vertex Pharmaceuticals needs to achieve nearly a 26% compound annual growth rate, significantly above the market's long-term average, despite its past decade's CAGR of 18.2%.
- Market Challenges: While Vertex's cystic fibrosis (CF) products will continue to drive growth, the shrinking patient population suggests that its CF business alone may struggle to deliver the necessary growth in the next decade, especially with patent expirations looming.
- Pipeline Candidates: Vertex's pipeline drugs inaxaplin and povetacicept aim to treat currently untreatable diseases, which could provide new growth avenues if approved, but flawless clinical execution will be crucial for success.
- Stock Investment Value: Even if Vertex cannot achieve a 100% success rate, its consistent revenue from CF products and new launches like Journavx make its stock a worthwhile investment, with a more diversified product lineup expected in the next decade.
See More
S&P 500 Bull Market Continues, Investor Confidence High
- Bull Market Performance: The S&P 500 finished 2025 with a remarkable 78% three-year increase, reflecting investor optimism particularly in high-growth sectors like artificial intelligence and weight loss drugs.
- Interest Rate Impact: The Federal Reserve's interest rate cuts have eased consumer financial pressure and facilitated borrowing for companies, which has driven stock prices and valuations higher, with the S&P 500's price-to-earnings ratio reaching historical highs.
- Valuation Fluctuations: Although the S&P 500 has shown little change recently, the Shiller CAPE ratio has declined for the first time, indicating that stock valuations may be coming down, which could signal potential market corrections ahead.
- Long-Term Investment Confidence: Despite potential short-term market fluctuations, historical data shows that the S&P 500 always recovers over the long term, encouraging investors to remain focused on economic reports and Fed signals to seize future investment opportunities.
See More
S&P 500 Index Enters Third Year of Bull Market
- Bull Market Performance: The S&P 500 finished 2023 with a double-digit gain, bringing its three-year increase to 78%, reflecting investor optimism particularly in high-growth sectors like artificial intelligence and weight loss drugs.
- Interest Rate Policy Impact: The Federal Reserve's interest rate cuts have eased consumer financial pressure and made borrowing easier for companies, further fueling stock market gains as investor expectations for economic improvement rise.
- Valuation Changes: The Shiller CAPE ratio for the S&P 500 recently declined for the first time in nearly a year, albeit slightly, marking the first sign of falling valuations; historical patterns suggest that such declines often precede stock market drops, prompting investor caution.
- Long-Term Investment Confidence: Despite potential short-term market fluctuations, the S&P 500 has historically shown resilience over the long term, indicating that investors holding quality stocks may experience limited impact from short-term downturns, with significant returns likely in the future.
See More
S&P 500 Index Surges Nearly 80% Over Three Years
- Bull Market Continuation: The S&P 500 index has entered a bull market since October 2023, achieving a double-digit gain by year-end, resulting in a 78% increase over three years, reflecting strong investor confidence in high-growth sectors, particularly in AI and weight loss drugs.
- Surging Valuations: As the S&P 500 has risen, stock valuations have reached historical highs, with the Shiller CAPE ratio exceeding 40 earlier this year, indicating optimistic expectations for future growth, yet raising concerns about sustainability.
- Interest Rate Policy Impact: The Federal Reserve's interest rate cuts have alleviated consumer burdens and facilitated corporate borrowing, further propelling the stock market; however, investor concerns regarding future rate changes may affect market sentiment, leading to volatility.
- Uncertain Market Outlook: Despite the recent slight decline in the Shiller CAPE ratio, historical data suggests that valuation drops often coincide with stock market declines, prompting investors to monitor economic reports and Fed communications to gauge future market direction.
See More
Novo Nordisk Faces Challenges and Opportunities Amid Setbacks
- Declining Performance: Novo Nordisk's disappointing guidance for fiscal year 2026 has led to a nearly 15% drop in stock price, reflecting pressures from intensified competition and government drug price negotiations that could impact long-term growth potential.
- New Product Launch: The launch of the oral version of Wegovy has seen rapid prescription growth, indicating its potential to generate new revenue streams despite market competition, which could help mitigate some of the company's challenges.
- Market Expansion: Eli Lilly's executive noted that Oral Wegovy is attracting mostly new patients, suggesting that it is not merely cannibalizing existing sales but effectively expanding the market, thereby enhancing Novo Nordisk's competitive position.
- Future Outlook: Despite the short-term sales decline challenges, Novo Nordisk is awaiting approval for new drugs like CagriSema and has several candidates in clinical trials; if progress is made, it could lead to a stock rebound, making it attractive for long-term investors.
See More
